A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity

Junko Takei, Mika Kato Kaneko, Tomokazu Ohishi, Manabu Kawada, Hiroyuki Harada, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

The epidermal growth factor receptor (EGFR) is a member of the human epidermal growth factor receptor (HER) familyofreceptortyrosinekinases;itisatransmembranereceptor involved in cell growth and differentiation. EGFR homodimers or heterodimers in combination with other HER members, such as HER2 and HER3, activate downstream signaling cascades in many types of cancer, including oral squamous cell carcinoma(OSCC).Thepresentstudyproducednovelanti-EGFR monoclonal antibodies (mAbs) possessing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and investigated antitumor activity. Mice were immunized with an EGFR-overexpressed glioblastoma cell line, LN229 (LN229/EGFR), after which ELISA was performed using recombinant EGFR. mAbs were subsequently selected according to their efficacy for LN229/EGFR, as determined via flow cytometry. After determining the subclass of mAbs, the EMab-17 (IgG2a, kappa) clone exhibited ADCC and CDC activities against two OSCC cell lines, HSC-2 and SAS. Furthermore, EMab-17 exerted antitumor activities against mouse xenograft models using HSC-2 and SAS, indicating that EMab-17 may be used in an antibody-based therapy for EGFR-expressing OSCC.

Original languageEnglish
Pages (from-to)2809-2816
Number of pages8
JournalOncology Letters
Volume19
Issue number4
DOIs
Publication statusPublished - 2020

Keywords

  • Antibody-dependent cellular cytotoxicity
  • Complement-dependent cytotoxicity
  • Epidermal growth factor receptor
  • Monoclonal antibody
  • Oral squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity'. Together they form a unique fingerprint.

Cite this